Annovis Bio, Inc. is a clinical-stage biotechnology firm based in Berwyn, Pennsylvania, focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer's and Parkinson's. Leveraging its proprietary platform, the company addresses the underlying mechanisms of neurodegeneration, aiming to restore neurological function and fulfill critical unmet medical needs in the aging population. With a promising pipeline backed by robust clinical trials, Annovis Bio offers a compelling investment prospect for institutional investors interested in groundbreaking advancements in neurology that may significantly improve patient outcomes. Show more

Location: 101 LINDENWOOD DRIVE, MALVERN, PA, UNITED STATES, 19355, Malvern, PA, 19355, USA | Website: https://www.annovisbio.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

59.8M

52 Wk Range

$1.11 - $5.50

Previous Close

$2.44

Open

$2.54

Volume

550,923

Day Range

$2.46 - $2.61

Enterprise Value

53.09M

Cash

15.29M

Avg Qtr Burn

-3.488M

Insider Ownership

15.45%

Institutional Own.

13.40%

Qtr Updated

06/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Buntanetap (ANVS401) Details Parkinson's disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Buntanetap (ANVS401) Details Alzheimer's disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.